• Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million
  • Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts
  • Monetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships

NEW HOPE, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of $6.1 million on September 14, 2026, as the first milestone payment in connection with the previously announced acquisition of Vivasure Medical Limited (“Vivasure”) by Haemonetics Corporation (NYSE: HAE, “Haemonetics”). This second payment follows the approximately $5 million upfront payment received in January 2026 and brings total cash proceeds received by Orchestra BioMed from the transaction to approximately $11 million.

Vivasure, an Ireland-based company pioneering next-generation technology for percutaneous vessel closure, had been a strategic holding of Orchestra BioMed since the Company’s formation. Haemonetics completed its acquisition of Vivasure on January 9, 2026, as previously announced.

The payment completes the approximately $11 million in proceeds previously disclosed as expected during 2026. Orchestra BioMed remains eligible to receive up to approximately $10 million in additional proceeds through future revenue earnouts, subject to the achievement of certain milestones, for total potential proceeds of up to $21 million.

Developed by Vivasure, the PerQseal® Elite system uses a proprietary bioabsorbable patch to seal large-bore arteriotomies and venotomies from inside the vessel, offering a sutureless, fully absorbable solution for structural heart and endovascular procedures. PerQseal Elite is not available for sale in the United States.

About Orchestra BioMed

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates – Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) – are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

About Haemonetics

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Haemonetics’ innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.

References to Websites and Social Media Platforms

References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

Investor Contact:
Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com

Media Contact:
Nina Premutico
Orchestra BioMed
npremutico@orchestrabiomed.com

MANITOWOC, Wis., Sept. 15, 2026 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electric vehicle (EV) charging stations and maintenance services solutions, today announced that a longtime customer has made a follow-on commitment to the Company for a new LED lighting project estimated to represent revenue of $10 million to $15 million. The new project is at additional locations operated by this retailer.

This latest commitment involves retrofitting interior LED Lighting and IoT system installations at selected locations not previously retrofitted by Orion. Orion maintains that this most recent expansion of work demonstrates the confidence that Orion has earned with this leading retailer over the course of numerous projects spanning several years.

The customer’s latest commitment is expected to be fulfilled on the basis of individual purchase orders, the timing of which is not certain at this time. However, Orion expects to recognize a significant majority of the revenue from this project in the second half of the current Fiscal Year 2027, which ends March 31, 2027.

As a result of today’s announcement, Orion also announced that it expects to achieve total revenue of $100 million to $102 million for FY 2027, representing an increase from its previous outlook of $95 million to $97 million. As previously announced, Orion expects FY’Q2 revenues to decrease compared to the recently announced FY’Q1 revenue of $25.7M. The Company continues to expect to achieve positive Adjusted EBITDA for the fiscal year as a whole.

“Orion has once again earned a significant increase in its scope of work on behalf of one of the biggest names in retailing,” said Orion Chief Executive Officer Sally Washlow. “Orion continues to add substantially to its workflow with this Global Fortune 50 company, as we expand our management of LED Lighting, IoT, Maintenance and Electrical Contracting. We are pleased to continue to earn increasing trust, confidence and business from this industry leader.”

About Orion Energy Systems
Orion provides energy efficiency and clean tech solutions, including LED lighting and controls, electrical vehicle (EV) charging solutions, and maintenance services. Orion specializes in turnkey design-through-installation solutions for large national customers as well as projects through ESCO and distribution partners, with a commitment to helping customers achieve their business and environmental goals with healthy, safe, and sustainable solutions that reduce their carbon footprint and enhance business performance.

For more information about Orion, please visit our website at www.orionlighting.com.

Safe Harbor Statement  
Certain matters discussed in this press release, are “forward-looking statements” intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements may generally be identified as such because the context of such statements will include words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or words of similar import. Similarly, statements that describe our future plans, objectives or goals, including business relationships with government customers, are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties that could cause results to differ materially from those expected including, but not limited to, the risks described in our filings with the Securities and Exchange Commission.

Shareholders, potential investors and other readers are urged to consider risks and uncertainties carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are made only as of the date of this press release and we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. More detailed information about factors that may affect our performance may be found in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov or at http://investor.oriones.com/ in the Investor Relations section of our Website. Except as required by applicable law, we assume no obligation to update any forward-looking statements publicly or to update the reasons why actual results could differ materially from those anticipated in any forward-looking statements, even if new information becomes available in the future.

Engage with Us
X: @OrionLighting and @OrionLightingIR
StockTwits: @OESX_IR

Investor Relations Contacts   
Per Brodin, CFO Robert Ferri
Orion Energy Systems, Inc.
pbrodin@oesx.com
Robert Ferri Partners
(415) 575-1589
robert.ferri@robertferri.com

Akropolis Group, UAB invites investors, analysts, and other stakeholders to join the webinar dedicated to presentation of group’s financial results of the first half-year 2026, scheduled on 28th September, 2026 at 13:00 (EEST). The presentation will be held in English.  

During the webinar, Gabrielė Sapon, CEO and Marius Žemaitaitis, CFO of Akropolis Group, UAB will introduce the group’s financial results of the first half-year 2026. After the presentation, attendees will have an opportunity to ask relevant questions. Due to limited webinar time, we encourage participants to submit their questions in the registration form or send them before the start of the webinar to olga.azarova@nasdaq.com. 

To join the webinar, please register via the following link:  https://nasdaq.zoom.us/webinar/register/WN_sW_x7TPFRie9m-GZLzh6bw 

Contacts: 
E–mail: IR@akropolis.lt 
Internet webpage: www.akropolis.eu 
Address: Ozo st. 25, Vilnius, Lithuania

For more information: 
Paulius Pocius
Head of Marketing and Communications
AKROPOLIS GROUP, UAB
+370 699 99566
paulius.pocius@akropolis.lt

The cooperation brings together the companies’ detection, threat analysis and physical interception capabilities into a unified and complete Counter-UAS architecture

KFAR SABA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (“ParaZero” or the “Company”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today announced the signing of a non-binding Memorandum of Understanding (“MOU”) with ThirdEye Systems Ltd. (TASE: THES), an Israeli defense technology company specializing in advanced electro-optical recognition and Counter-UAS systems.

The non-binding MOU establishes a framework for the companies to explore the development, integration, and commercialization of a complete Counter-UAS solution combining ThirdEye’s advanced detection and sensor capabilities with ParaZero’s DefendAir net-based physical interception technology , which shall be subject to the execution of definitive documentation..

The cooperation includes the creation of a complete integrated detect-to-defeat architecture covering the full Counter-UAS engagement cycle — from detection and identification of an approaching aerial threat, through threat analysis and engagement management, to controlled physical interception and neutralization. the companies will initially focus on protecting armored vehicle platforms from the rapidly evolving drone threats and may also explore applications for critical infrastructure, strategic sites, and other sensitive assets requiring an integrated detection-to-interception capability.

The already field-tested architecture is intended to connect detection, threat analysis, engagement management, safety, and controlled physical interception within a unified Counter-UAS system. This approach reflects the growing operational requirement for solutions capable of supporting the full engagement cycle, from identifying an approaching drone to physically stopping it.

“Protecting armored vehicles and strategic assets from evolving drone threats requires detection, decision-making, and interception capabilities to operate as one integrated system,” said Ariel Alon, CEO of ParaZero Technologies. “ThirdEye brings advanced electro-optical detection and AI-driven recognition capabilities, while ParaZero provides the physical interception layer through DefendAir. This MOU creates a framework to combine theses technologies into a practical and complete Counter-UAS architecture.”

Lior Segal, CEO of ThirdEye Systems, added:

“Our collaboration with ParaZero represents a significant force multiplier for both our company and our operational customers. The ability to provide field forces with a comprehensive protection solution, from the initial detection of a threat through to its actual interception, is critical, particularly for armoured vehicles and sensitive assets. We are confident that the combined system will deliver significant value to defence markets in Israel and around the world.”

About ParaZero Technologies

ParaZero Technologies Ltd. (Nasdaq: PRZO) is an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry.

Founded in 2014 by aviation professionals and drone industry veterans, ParaZero develops intelligent, mission-ready technologies for defense and advanced aerial applications.

The Company’s DefendAir product family provides a controlled, non-explosive, net-based physical interception capability designed for integration across personal, mobile, autonomous and fixed-site Counter-UAS systems.

For more information, visit ParaZero https://parazero.com/

About ThirdEye Systems

Founded in 2010, ThirdEye Systems is a pioneering developer of advanced AI-based solutions for optical systems and autonomous platforms, with a strong focus on defense and security applications.

The company specializes in edge AI applications and provides innovative real-time image processing technology, enabling tracking and control under challenging operational conditions. ThirdEye Systems’ solutions deliver rapid and high-quality responses to evolving threats, including protection against UAVs and drones.

The company’s products are designed to be reliable, mobile, and operational 24/7, providing an optimal solution for operational units in the field. 

ThirdEye Systems’ solutions set a new standard in integrating artificial intelligence with defense and security systems, advancing the capabilities of the field.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding ParaZero’s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the execution of definitive documentation, the parties’ intention to explore the development, integration and commercialization of a complete Counter-UAS solution, the anticipated capabilities, performance and potential applications of the proposed system, the potential benefits of the collaboration, the possibility of future commercial arrangements between the parties, and the potential adoption of the integrated solution by defense, security and critical infrastructure customers.. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed with the SEC on March 26, 2026. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. ParaZero is not responsible for the content of third-party websites.

Investor Relations Contact:

Michal Efraty
Investor Relations
michal@efraty.com

CHICAGO, Sept. 15, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that Board member Ramiro Guerrero, JD, LL.M. has increased his ownership stake in the Company through open market purchases totaling approximately $252,284. A total of 185,078 shares of MAIA common stock were acquired by Mr. Guerrero between August 20, 2026, and September 10, 2026, at an average common stock price of $1.36. MAIA also announced that 73,000 shares of MAIA common stock were acquired by Founder and CEO Vlad Vitoc, M.D. on September 14, 2026, at an average common stock price of $1.37.

“Our increased investments reflect the confidence we share across our leadership team in MAIA’s science, clinical strategy and long-term commercial potential,” said Dr. Vitoc. “With a growing body of clinical evidence supporting the ateganosine program, we believe MAIA is entering an increasingly important period in its development.”

“As MAIA has stated previously, its ongoing pivotal Phase 3 trial offers a statistically high probability of technical success,” Mr. Guerrero added. “I continue to believe MAIA is well positioned to create a great deal of value for its shareholders over time.”

MAIA’s ongoing pivotal Phase 3 trial THIO-104 evaluates ateganosine sequenced with checkpoint inhibitor cemiplimab versus investigator’s choice in third-line non-small cell lung cancer (NSCLC). Statistical assessments of ateganosine suggest a high probability of technical success and potential early full commercial approval if Phase 3 interim data is consistent with Phase 2 THIO-101 trial results. MAIA recently announced positive initial efficacy data from the ongoing Phase 2 THIO-101 clinical trial expansion, Part C, with third-line studies showing a disease control rate (DCR) of 90.5%1 in the efficacy evaluable population who had at least one tumor scan after starting treatment. 

As of September 14, 2026, MAIA’s directors and officers hold a 21.34% stake in the Company.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com


1 As of July 6, 2026

LOWELL, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) — MACOM Technology Solutions Inc. (“MACOM”), a leading supplier of semiconductor products, today announced it will showcase its latest optical and high speed connectivity technologies at the European Conference on Optical Communication (ECOC) 2026, taking place September 21 – 23, 2026, in Málaga, Spain. Visitors to Stand 1055 can learn about MACOM’s broad portfolio of solutions designed to support the growing bandwidth, performance and power efficiency demands of AI infrastructure, cloud data centers, telecommunications networks and emerging optical architectures.

MACOM continues to advance the critical analog and optoelectronic technologies that enable more efficient data transmission throughout datacenter AI networks. The company will demonstrate its IC solutions in a variety of applications in optical transceivers, active copper cables, PCIe interconnects, coherent networking, optical access networks and near packaged optics (NPO).

“Demand for higher bandwidth and lower power consumption continues to drive innovation across the optical communications ecosystem. We’re excited to showcase our portfolio which is helping customers build the next generation of optical and connectivity infrastructure,” said Stephen G. Daly, President and Chief Executive Officer, MACOM.

Featured Demonstrations
MACOM will present live demonstrations featuring:

  • 3.2T Optical Solutions, featuring 448 Gbps/lane modulator drivers, transimpedance amplifiers and photodetectors.
  • 1.6T Active Copper Cable Solution, demonstrating 224 Gbps/lane equalizers and cable drivers designed to deliver high speed copper connectivity.
  • 1.6T Optical Products incorporating 224 Gbps/lane photodetectors, laser drivers and transimpedance amplifiers.
  • PCIe Connectivity showcasing Optical PCIe® 6.0 and Copper PCIe® 7.0 technologies for next generation compute and storage architectures.
  • NPO featuring 112 and 226 Gbps/lane drivers, transimpedance amplifiers and photodetectors.
  • 800G Scale Out Networks utilizing 400 Gbps-per-wavelength coherent drivers and transimpedance amplifiers.
  • 5G Advanced and 6G Fronthaul highlighting linear drivers and TIAs for SFP56/SFP112 LPO.

Additional Product Display
MACOM will also feature a dedicated display highlighting its technologies for:

  • Free Space Optics (FSO) applications supporting high speed optical communication links.
  • RF over Fiber (RFoF) solutions that enable the transport of radio frequency signals over optical fiber for communications, satellite communications and other high performance networking applications.


Visit MACOM at ECOC 2026

Event:         European Conference on Optical Communication (ECOC) 2026
Dates:         September 21 – 23, 2026
Location:    Málaga, Spain
Stand:         1055

To schedule a meeting with MACOM during ECOC 2026, please visit https://www.macom.com/meet.

About MACOM
MACOM designs and manufactures semiconductor products for telecommunications, industrial and defense and data center applications. Headquartered in Lowell, Massachusetts, MACOM has design centers and sales offices throughout North America, Europe and Asia. MACOM is certified to the ISO9001 international quality standard and ISO14001 environmental management standard. To learn more, visit https://www.macom.com/.

Company Contact:
MACOM Technology Solutions Inc.
Stephen Ferranti
Senior Vice President, Corporate Development and Investor Relations
P: 978-656-2977
E: stephen.ferranti@macom.com

  • ROLR platform now available to select participants for controlled real-world testing and performance optimization
  • The beta version will generate operating data and feedback from select invite-only users across onboarding, trading, payments, compliance, customer service and platform performance

LAS VEGAS, Nevada, Sept. 15, 2026 (GLOBE NEWSWIRE) — High Roller Technologies, Inc. (“High Roller” or the “Company”) (NYSE: ROLR), a publicly traded online gaming and prediction markets company, today launched the closed beta of its ROLR™ prediction markets platform with a select group of invited participants. As announced on September 2, 2026, the invitation-only beta represents the Company’s final controlled testing and optimization phase ahead of its commercial launch targeted for late October 2026.

“The launch of the ROLR beta version moves the platform from development and integration into controlled, real-world use,” said Seth Young, Chief Executive Officer of High Roller Technologies. “The platform’s core capabilities are functional, our technology and service integrations are in place, and invited participants can now experience the product from onboarding through contract settlement. The data and feedback generated during this phase will allow us to refine the experience, validate our operating processes and prepare for our commercial launch planned for late October 2026.”

Beta Platform Capabilities and Experience

The ROLR platform’s core consumer-facing and operational capabilities are available for testing within the closed beta environment, including account registration and onboarding, identity verification, geolocation, account funding, market discovery, order entry, trading, position management, contract settlement, withdrawals and customer service.

During the beta test, invited participants selected by the Company will use the platform under controlled, live-platform conditions, enabling High Roller to collect operating data, evaluate user behavior and obtain direct feedback before expanding access to the broader market. The Company plans to use the beta period to validate and optimize the customer experience while confirming platform stability, scalability and operational readiness. The closed beta is not open to the general public.

Beta Version Objectives

High Roller intends to use the beta version to collect and evaluate data across key elements of the ROLR platform and customer experience. The beta will initially be limited to select invited participants. High Roller expects to evaluate the resulting data and feedback on an ongoing basis and make targeted product and operational refinements before the planned commercial launch.

ROLR’s planned commercial rollout is also supported by the Company’s previously announced strategic marketing and distribution partners:

  • Lines.com, a sports media and content platform owned by Spike Up Media;
  • Forever Network, a global social-first sports media and fan-engagement company; and
  • Leverage Game Media, a digital media company operating sports, gaming, cryptocurrency and entertainment-focused communities.

High Roller expects to commence the commercial launch of the ROLR prediction markets platform by the end of October 2026, subject to the successful completion of the closed beta and final technical and operational readiness.

About High Roller Technologies, Inc.

High Roller Technologies, Inc. (NYSE: ROLR) is a publicly traded online gaming and prediction markets company, known for its innovative casino brands High Roller and Fruta, and its prediction markets brand, ROLR. The Company delivers cutting-edge real-money consumer facing products that are intuitive and user-friendly. With a diverse portfolio of over 6,000 premium online casino games from more than 90 leading game providers, High Roller Technologies offers an immersive and engaging gaming experience in the rapidly expanding multi-billion-dollar iGaming industry. As an award-winning operator, High Roller Technologies continues to redefine the future of market engagement through innovation, performance, and a commitment to excellence.

For more information, please visit the Company’s investor relations website and follow High Roller Technologies on X, Facebook, and LinkedIn.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, the commercial launch timing of the ROLR™ prediction markets platform. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the ability of the Company to successfully complete the closed beta on the anticipated timeline, risks related to platform stability, scalability and technical readiness, the regulatory environment applicable to prediction markets, the Company’s ability to attract and retain platform users, and general market and economic conditions and such factors as discussed throughout Part I, Item 1A. Risk Factors and Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the year ended December 31, 2025, Part I. Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations and Part II, Item 1A. Risk Factors, of our quarterly report on Form 10-Q for the quarter ended June 30, 2026 and in our other filings with the Securities and Exchange Commission. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact
Investor Relations
ir@highroller.com
800-460-1039

Proprietary on-device training built to dynamically adapt to real-world environments

CHANDLER, Ariz., Sept. 15, 2026 (GLOBE NEWSWIRE) — AnalogAI has chosen memBrain™ Synaptic Analog Generative Engine (SAGE) neuromorphic hardware intellectual property (IP) from Microchip Technology’s (Nasdaq: MCHP) Silicon Storage Technology® (SST®) subsidiary for its real-world edge AI processors. AnalogAI edge AI processors feature a hardware aware proprietary algorithm designed to simultaneously train and run inference on AI models in real-world environments.

AnalogAI is utilizing SST’s memBrain SAGE IP to deliver high levels of analog compute-in-memory (aCIM) performance at or below one watt for ultra-low power edge applications. By leveraging the robust silicon proven SST memBrain SAGE IP based on SST SuperFlash®, AnalogAI is developing new capabilities for real-world inference applications such as environment adapting humanoid robots, drones and vehicles.

“AnalogAI is pursuing innovative co-optimized solutions for edge AI inference that enable edge devices to adapt real-time to sudden changes in the environment,” said Mark Reiten, senior vice president of Microchip’s Intelligent Compute business unit. “As the core inference engine for AnalogAI’s first products, SST memBrain SAGE IP delivers the necessary compute performance coupled with the power efficiency AnalogAI requires to meet their application targets. We are pleased to welcome AnalogAI as the newest licensee of our SST memBrain IP, joining our rapidly expanding ecosystem.”

SST memBrain SAGE IP features:

  • memBrain Tensor In-Memory Logic Element (TILE)
    • memBrain solution optimized ESF3 bitcell which stores up to 8 bpc at nanoamp levels
    • memBrain solution custom array, decoders and driver circuitry
  • Optimized DACs and ADCs
  • Summator and high voltage bias circuitry
  • Nanoamp level bitcell control logic
  • memBrain proprietary test circuitry
  • SST memBrain technology documentation and simulation models
  • Full IP integration service and support

“AnalogAI selected SST’s memBrain SAGE IP after an industry-wide search of available offerings and determined the silicon-proven memBrain SAGE IP best enabled us to accelerate our development time while still achieving the ultra-low-power and high performance required in our market segment,” said Jaejun Lee, AnalogAI’s chief executive officer. “Analog Compute-in-Memory is a rapidly emerging field, and at AnalogAI we are pioneering new functionality for edge AI devices requiring real-world adaptation.”

SST’s memBrain SAGE IP has been developed and deployed in 40 nm and 28 nm foundry processes using production-ready SuperFlash memory. The current technology roadmap includes 22 nm memBrain SAGE IP development. Designed to provide reliable, high-performance and low-power non-volatile storage directly on the chip, SuperFlash memory is widely used in applications that require fast access times, high endurance and data retention without the need for external memory components.

Pricing and Availability
Customers interested in SST’s memBrain IP solutions and SuperFlash technology should access the SST website or contact a regional SST sales executive for details. Those interested in AnalogAI’s products should visit the AnalogAI website or contact the AnalogAI team at contact@analog-ai.com.

Resources
High-res images available through Flickr or editorial contact (feel free to publish):

About Microchip Technology:
Microchip Technology Inc. is a broadline supplier of semiconductors committed to making innovative design easier through total system solutions that address critical challenges at the intersection of emerging technologies and durable end markets. Its easy-to-use development tools and comprehensive product portfolio supports customers throughout the design process, from concept to completion. Headquartered in Chandler, Arizona, Microchip offers outstanding technical support and delivers solutions across the industrial, automotive, consumer, aerospace and defense, communications and computing markets. For more information, visit the Microchip website at www.microchip.com.

About Silicon Storage Technology (SST):
Microchip Technology’s SST subsidiary is a leading provider of embedded flash technology. SST develops, designs, licenses and markets a diversified range of proprietary and patented SuperFlash memory technology solutions for the consumer, industrial, automotive and Internet of Things (IoT) markets. SST was founded in 1989, went public in 1995 and was acquired by Microchip in April 2010. SST is now a wholly owned subsidiary of Microchip and is headquartered in San Jose, Calif. For more information, visit the SST website at www.sst.com.

About AnalogAI:
AnalogAI builds edge AI processors that train directly on the device, allowing robots, drones and vehicles to adapt to changing physical environments in real time while running at ultra-low power. Its analog compute-in-memory architecture performs on-device training and inference in a single low-power design, moving beyond the inference-only approach of conventional edge AI hardware. AnalogAI targets physical-world edge applications where systems must keep adapting after deployment, from robotics to autonomous machines. The company is headquartered in the Seoul area, South Korea. For more information, visit www.analog-ai.com.

Note: The Microchip name and logo, the Microchip logo, Silicon Storage Technology, SST and SuperFlash are registered trademarks of Microchip Technology Incorporated in the U.S.A. and other countries. memBrain is a trademark of Microchip Technology Inc. in the U.S.A. and other countries. All other trademarks mentioned herein are the property of their respective companies.

Editorial Contact: Partner Media Contact:  
Brian Thorsen Jaejun Lee  
480-792-7182 jaejun.lee@analog-ai.com  
Brian.Thorsen@microchip.com    

This press release was published by a CLEAR® Verified individual.

SANTA ANA, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company’s lead investigational program, troculeucel, at the 4th Great Bay Cell and Gene Therapy Forum, taking place September 22-23, 2026, in Guangzhou, China.

NKGen Presentation Details:
Title: Autologous Enhanced Natural Killer Cell Therapy for Neurodegenerative Diseases
Track: Next Gen Cell Therapy Track 3 — Autoimmunity & Universal Cell Therapy
Location: Ballroom A
Date & Time: Wednesday, September 23, 2026, at 9:35– 10:00 a.m. China Standard Time (CST)/
Tuesday, September 22, 2026, at 9:35-10:00 p.m. Eastern Time (ET)

Dr. Song’s presentation will explore the application of troculeucel in neurodegenerative diseases, with a focus on its proposed mechanism of action, changes observed in neuroinflammatory and protein biomarkers in cerebrospinal fluid, and clinical experience in patients with Alzheimer’s disease. The presentation will also discuss Parkinson’s disease and frontotemporal dementia as potential areas for further evaluation of troculeucel.

A copy of the presentation will be available on the Company’s website under the Scientific Publications section following the event. Additionally, previously disclosed scientific data on troculeucel for neurodegenerative disease can be accessed on the same page. For the latest updates on the Company’s clinical trials and regulatory announcements, please visit the Company’s News page.

About Troculeucel
Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name (“INN”) for SNK01 assigned by the World Health Organization (“WHO”). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen’s journey toward bringing this therapy to market.

About NKGen Biotech
NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.

Forward-Looking Statements 
Statements contained in this press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s anticipated timing and content of its filings with the U.S. Securities and Exchange Commission (the “SEC”) and other public disclosures; the Company’s plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company’s expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company’s ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen’s ability to raise additional funding to complete the development of its product candidates. Additional risks include uncertainties related to the Company’s acquisition of a majority interest in NKGen Biotech Korea Co., Ltd., including risks regarding the future performance of NKGen Biotech Korea Co., Ltd.’s business, the Company’s ability to successfully integrate NKGen Biotech Korea Co., Ltd.’s operations, personnel, and technologies, potential challenges in realizing expected synergies and cost savings, and risks that the Company may not achieve the anticipated strategic, financial, or operational benefits of the acquisition on the expected timeline or at all. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in the Company’s filings and reports, which may be accessed for free by visiting the SEC’s website at www.sec.gov and on the Company’s website under the subheading “Investors—Financial and Filings”. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Internal Contact:
Denise Chua, MBA, CLS, MLS (ASCP)
SVP, Corporate Affairs
949-396-6830
dchua@NKGenbiotech.com

External Contacts:
Kevin Gardner
Managing Director
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com

NETSOL and BMO Sign Transcend Finance Agreement

Najeeb Ghauri, Founder and Chief Executive Officer of NETSOL Technologies (seated, left), and Tom Kritzer, Head, U.S. Equipment Finance at BMO (seated, right), sign the agreement bringing BMO Equipment Finance onto NETSOL's Transcend Finance platform, joined by David Abplanalp, Managing Director and Chief Operating Officer, Equipment Finance at BMO (standing, left), and Faizaan Ghauri, President, Americas at NETSOL Technologies (standing, right).
Najeeb Ghauri, Founder and Chief Executive Officer of NETSOL Technologies (seated, left), and Tom Kritzer, Head, U.S. Equipment Finance at BMO (seated, right), sign the agreement bringing BMO Equipment Finance onto NETSOL’s Transcend Finance platform, joined by David Abplanalp, Managing Director and Chief Operating Officer, Equipment Finance at BMO (standing, left), and Faizaan Ghauri, President, Americas at NETSOL Technologies (standing, right).

NETSOL CEO Najeeb Ghauri At BMO Office

Tom Kritzer, Head, U.S. Equipment Finance at BMO (left), and Najeeb Ghauri, Founder and Chief Executive Officer of NETSOL Technologies (right), at BMO's offices following the agreement signing.
Tom Kritzer, Head, U.S. Equipment Finance at BMO (left), and Najeeb Ghauri, Founder and Chief Executive Officer of NETSOL Technologies (right), at BMO’s offices following the agreement signing.

ENCINO, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK), a provider of AI-enabled solutions and services powering OEMs, dealerships and financial institutions to sell, finance and lease assets, has signed a contract with BMO in the United States to use NETSOL’s Transcend Finance platform for its equipment finance portfolio.

In moving to NETSOL’s solution, BMO will manage equipment financing assets through the advanced capabilities of Transcend Finance, setting a new standard for efficiency, customer experience, and digital transformation in the financial services sector. This contract marks BMO’s transition from NETSOL’s legacy LeasePak platform to Transcend Finance.

Built on NETSOL’s global experience, Transcend Finance is a next-generation, AI-powered platform that unifies originations, servicing, and wholesale finance. Designed for scalability and flexibility, it enables lenders, captives and commercial financiers to accelerate digital transformation, launch new business models, and manage the complete finance lifecycle with intelligence and precision. This upgrade will position BMO at the forefront of digital asset finance solutions, driving agility and growth in a competitive marketplace.

“This upgrade with BMO is a testament to the enduring strength of our partnership and the unparalleled value NETSOL brings to one of the leading banks in North America,” said Najeeb Ghauri, Founder and CEO of NETSOL Technologies, Inc. “For over 30 years, NETSOL has been privileged to support BMO’s growth and innovation, delivering robust, reliable solutions. With the transition to our Transcend Finance platform, BMO is poised to unlock new levels of operational efficiency, risk management and customer engagement.”

“This deal embodies our commitment to continuous innovation and client success,” he added. “We are proud to support BMO as they lead the industry forward with a modern, flexible platform that empowers them to adapt quickly in an evolving market and deliver exceptional value to their customers.”

About BMO Financial Group
BMO Financial Group is the eighth largest bank in North America by assets, with total assets of $1.5 trillion as of July 31, 2026. Serving clients for more than 200 years, BMO provides a broad range of personal and commercial banking, wealth management, global markets and investment banking products and services across Canada, the United States, and select markets globally. BMO is innovating for business value, by deploying and integrating human, digital and artificial intelligence to personalize client experiences, augment teams, and automate its business responsibly. Driven by its purpose, to Boldly Grow the Good in business and life, BMO is committed to driving positive change in the world, and making progress for a thriving economy, sustainable future, and stronger communities.

About NETSOL Technologies 
NETSOL Technologies delivers state-of-the-art solutions for the asset finance and leasing industry, serving automotive and equipment OEMs, auto captives and financial institutions across over 30 countries. Since its inception in 1997, NETSOL has been at the cutting edge of technology, pioneering innovations with its asset finance solutions and leveraging advanced AI and cloud services to meet the complex needs of the global market. Renowned for its deep industry expertise, customer-centric approach and commitment to excellence, NETSOL fosters strong partnerships with its clients, ensuring their success in an ever-evolving landscape. With a rich history of innovation, ethical business practices and a focus on sustainability, NETSOL is dedicated to empowering businesses worldwide, securing its position as the trusted partner for leading firms around the globe. 

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the company’s products and services, expectations for future operations, and other statements that are not historical facts. These forward-looking statements may be identified by terminology such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “projects,” “targets,” and similar expressions. These statements are not guarantees of future performance and are subject to a number of risks, uncertainties, and assumptions that are difficult to predict. Factors that could cause actual results to differ materially include, but are not limited to, the timing of customer go-lives and contract renewals, the rate of adoption of AI-enabled product capabilities, foreign currency volatility, and other factors discussed in NETSOL’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. NETSOL undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investor Relations Contact:
Investor Relations
(818) 222-9195
investors@netsoltech.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/091fd816-5449-4627-83c5-4bf1b983571b

https://www.globenewswire.com/NewsRoom/AttachmentNg/eab45107-6b4f-488a-800b-e7c013c34f85

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.